Abstract 684P
Background
SHR-A1811 is a novel ADC consisting of a humanized, anti-HER2 IgG1 mAb bound to a DNA topoisomerase I inhibitor payload via a cleavable, tetrapeptide-based linker. We conducted a phase 1 trial to assess SHR-A1811 in HER2-expressing locally advanced or metastatic GC/GEJ and CRC.
Methods
Patient (pts) who had failed or had no available/applicable standard treatment were enrolled. Pts were given SHR-A1811 at 3.2, 4.8, 6.4 and 8.0 mg/kg (Q3W, iv) in an i3+3 dose-escalation (DE) scheme, followed by PK expansion at selected tolerable doses and then clinical expansion at RP2D. The primary endpoints were DLT, safety and RP2D.
Results
As of data cutoff (Apr. 21, 2023), 98 pts were enrolled, including 55 GC/GEJ and 43 CRC pts (HER2-positive, 72.7%/86.0%; ≥2 lines of prior therapy, 29.1%/67.4%). During DE, 1 DLT (grade 4 decreased platelet count) occurred at 8.0 mg/kg. Combined with dose-proportional systemic exposure of SHR-A1811, total antibody, and payload at 3.2-8.0 mg/kg, and general treatment tolerability and an ORR of 50.0% (6/12) at 6.4 mg/kg during DE and PK expansion, 6.4 mg/kg was established as RP2D. Overall, the respective ORR in GC/GEJ and in HER2-positve GC/GEJ at RP2D were 38.2% (21/55; 95% CI 25.4-52.3) and 43.8% (14/32; 95% CI 26.4-62.3); the corresponding ORR in CRC were 44.2% (19/43; 95% CI 29.1-60.1) and 46.9% (15/32; 95% CI 29.1-65.3). Additional tumor response data are shown in the table. The respective 6-mo PFS rates in GC/GEJ and in HER2-positve GC/GEJ at RP2D were 71.0% (95% CI 54.0-82.7) and 73.9% (95% CI 52.1-86.9); the corresponding rates in CRC were 75.6% (95% CI 57.9-86.6) and 85.5% (95% CI 65.6-94.3). Grade ≥3 TRAEs occurred in 67 of 98 pts (68.4%), with all events occurring in ≥10% being hematotoxicities. No interstitial lung disease was reported. Table: 684P
Efficacy outcomes
All GC/GEJ∗ (N=55) | HER2-positive GC/GEJ† 6.4 mg/kg (N=32) | All CRC∗ (N=43) | HER2-positive CRC† 6.4 mg/kg (N=32) | |
ORR‡, % (n/N; 95% CI) | 38.2% (21/55; 25.4-52.3) | 43.8% (14/32; 26.4-62.3) | 44.2% (19/43; 29.1-60.1) | 46.9% (15/32; 29.1-65.3) |
DCR, % (n/N; 95% CI) | 83.6% (46/55; 71.2-92.2) | 84.4% (27/32; 67.2-94.7) | 86.1% (37/43; 72.1-94.7) | 93.8% (30/32; 79.2-99.2) |
TTR‡, median (range), mo | 1.5 (1.3-4.6) | 1.4 (1.3-3.0) | 2.8 (1.2-7.1) | 2.9 (1.5-7.1) |
6-mo PFS, % (95% CI) | 71.0% (54.0-82.7) | 73.9% (52.1-86.9) | 75.6% (57.9-86.6) | 85.5% (65.6-94.3) |
∗HER2-expressing, IHC1+, 2+, or 3+ or ISH+. †HER2-positive, IHC3+ or IHC2+/ISH+. ‡Unconfirmed response.
Conclusions
SHR-A1811 showed an acceptable safety profile and promising clinical activity in pts with HER2-expressing GC/GEJ and CRC. Further investigation was warranted.
Clinical trial identification
NCT04513223.
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Hengrui Pharmaceuticals, Co., Ltd.
Funding
Jiangsu Hengrui Pharmaceuticals, Co., Ltd.
Disclosure
Y. Shen, N. Dou, C. Huang: Financial Interests, Personal, Full or part-time Employment: Hengrui. All other authors have declared no conflicts of interest.
Resources from the same session
710P - A retrospective study on the safety and adequacy of fresh biopsies for next generation sequencing in early-phase clinical trials
Presenter: Edoardo Crimini
Session: Poster session 17
711TiP - A phase I/II, first-in-human, open-label, dose-escalation study of TAK-186, an EGFR × CD3ε COBRA T cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors
Presenter: Andrew Weickhardt
Session: Poster session 17
712TiP - A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
Presenter: Angela Alistar
Session: Poster session 17
713TiP - A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation
Presenter: Ibiayi Dagogo-Jack
Session: Poster session 17
714TiP - A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors
Presenter: Stephen Luen
Session: Poster session 17
715TiP - ARTS-021-1001: Phase I/II study of ARTS-021, a potent, oral administrated, selective CDK2 inhibitor, in advanced or metastatic solid tumors
Presenter: Yan Wang
Session: Poster session 17
716TiP - DETERMINE: A pioneering UK precision medicine trial for rare cancers
Presenter: Gary Middleton
Session: Poster session 17
717TiP - An open-label, multicentre, dose-escalation, first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of OATD-02 (dual arginase 1 and arginase 2 inhibitor) in patients with selected advanced and/or metastatic solid tumors
Presenter: Marta Dudek
Session: Poster session 17
718TiP - DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy
Presenter: Elizabeth Moser
Session: Poster session 17
719TiP - A phase I/Ib study of the Werner (WRN) helicase inhibitor HRO761 as single agent and in combination with irinotecan or tislelizumab in patients with microsatellite instability-high (MSIhi) or mismatch repair deficient (dMMR) advanced solid tumors
Presenter: Michele Moschetta
Session: Poster session 17